News

MPR2d
FDA to Review Arexvy for 18 to 49-Year-Olds at Increased RSV Disease Risk
Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...
Stocktwits on MSN3d
GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance
GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine ...
Pharmabiz1d
GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk
GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...
Medical Dialogues2d
GSK application for expanded RSV vaccine Arexvy use for adults 18-49 accepted for review by USFDA
London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...
Pharmaceutical Technology on MSN3d
GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients
The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...
GSK seeks FDA nod for expanded use of RSV vaccine in adults
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...
Explore more
FiercePharma2d
Regulatory tracker: FDA accepts GSK expansion filing for RSV vaccine Arexvy
The company is seeking approval for Arexvy to be used in adults ages 18 to 49 who are at an increased risk for severe infection, GSK said in a July 14 press release.The FDA has now accepted the ...
FDA accepts application for GSK's Arexvy, Ashmore assets under management up $1.4bn in Q4
OPEN The FTSE 100 was expected to open 9.7 points lower ahead of the bell on Monday after wrapping up the previous session 0.38% softer at 8,941.12.
Devdiscourse2d
Health Sector Buzz: Mergers, Drugs, and CEO Shake-ups
Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...
New York Post2y
World's first RSV vaccine approved by FDA - New York Post
The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.
Seeking Alpha1y
Arexvy Puts GSK Back On The Growth Prescription (Rating Upgrade)
Arexvy dominates U.S. retail vaccine market in Q3; management optimistic but mindful of competitive landscape. Investment recommendation: "Speculative Buy" on GSK, ...
Vox2y
An RSV vaccine has been approved by the FDA. It’s a huge deal. - Vox
Arexvy is just the first downstream result of this discovery to be approved by the FDA, and more will likely follow soon. Pfizer’s RSV vaccine for adults will probably be approved later this ...